The Food and Drug Administration approved Ranbaxy's Ohm Laboratories in New Jersey to make the generic version of Diovan, a blood pressure drug from Novartis. Ranbaxy Laboratories won U.S. approval to ...

TOKYO/MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd (NSI:SUNPHARMA.NS - News) has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd (NSI:RANBAXY.NS - News) for $3.2 billion, betting it ...

PRINCETON, N.J., Aug. 20 -- Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug ...

WASHINGTON/MUMBAI (Reuters) - Ranbaxy Laboratories Ltd (RANB.NS) has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill ...

Ranbaxy Laboratories Signs A New R&D Agreement With GlaxoSmithKline; Ranbaxy Could Receive Over $100 Million PRINCETON, N.J., Feb. 6 -- Ranbaxy Laboratories Limited (Ranbaxy) announced today that the ...

India's Sun Pharmaceutical Industries said it will buy Ranbaxy Laboratories in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker from two firms struggling with ...

An India-based generic drug giant, Ranbaxy Laboratories, will pay Oregon $2.3 million after last year admitting to crimes involving the selling of substandard medicines. Though officials say the ...

Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) ("Ranbaxy"), today announced that it has received final approval from the U.S.

India’s Sun Pharmaceutical Industries is buying troubled generic drug maker Ranbaxy Laboratories in a $4-billion deal, the companies said Monday. The combined company will be India’s biggest ...

Ranbaxy Laboratories is the largest pharmaceutical company in India, focusing on the research, development, and marketing of generic drugs. When the performance of its SAP enterprise resource planning ...

Daiichi Sankyo claimed it had been deceived when its venture into Indian generic drug manufacturing turned into a regulatory maelstrom that eventually led it to unload Ranbaxy Laboratories at a loss.

The proposed sale of Ranbaxy Laboratories to Sun Pharmaceutical closes a troubled chapter for the Indian generic drug maker's owner, Japan's Daiichi Sankyo. If the deal is successful, Sun and Ranbaxy ...